<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005165.pub2" GROUP_ID="LIVER" ID="464404011912344277" MERGED_FROM="" MODIFIED="2008-11-10 01:04:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.4&lt;/p&gt;&lt;p&gt;Old title: Probiotics for nonalcoholic fatty liver disease and/or steatohepatitis&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:47 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="02" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-10 01:04:42 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis</TITLE>
<CONTACT>
<PERSON ID="19556" MODIFIED="2008-11-10 00:59:07 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Flavio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lirussi</LAST_NAME>
<SUFFIX>M.D., Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>fli@ihd.euro.who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Scientist, Socioeconomic Determinants of NCDs</DEPARTMENT>
<ORGANISATION>WHO Regional Office for Europe, European Office for Investment for Health and Development</ORGANISATION>
<ADDRESS_1>Campo Santo Stefano, San Marco 2847</ADDRESS_1>
<ADDRESS_2/>
<CITY>Venice</CITY>
<ZIP>I-30124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 041 279 3865</PHONE_1>
<PHONE_2>+39 041 279 3841</PHONE_2>
<FAX_1>+39 041 279 3869</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-10 00:59:03 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="19556" MODIFIED="2008-11-10 00:58:45 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Flavio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lirussi</LAST_NAME>
<SUFFIX>M.D., Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>fli@ihd.euro.who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Scientist, Socioeconomic Determinants of NCDs</DEPARTMENT>
<ORGANISATION>WHO Regional Office for Europe, European Office for Investment for Health and Development</ORGANISATION>
<ADDRESS_1>Campo Santo Stefano, San Marco 2847</ADDRESS_1>
<ADDRESS_2/>
<CITY>Venice</CITY>
<ZIP>I-30124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 041 279 3865</PHONE_1>
<PHONE_2>+39 041 279 3841</PHONE_2>
<FAX_1>+39 041 279 3869</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95D3333182E26AA201C330AA821DDD07" MODIFIED="2008-11-10 00:58:51 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ezio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mastropasqua</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>e.mastrop@tiscalinet.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Ospedale di Este</ORGANISATION>
<ADDRESS_1>Via S Fermo</ADDRESS_1>
<ADDRESS_2/>
<CITY>Padova</CITY>
<ZIP>35042 Este</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0429 6183 55</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19557" MODIFIED="2008-11-10 00:58:58 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Serena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Orando</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>serena.orando@libero.it, piediblu@libero.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Instituto di Anestesia e Rianimazione</DEPARTMENT>
<ORGANISATION>Universitá Degli Studi di Firenze</ORGANISATION>
<ADDRESS_1>Azienda Ospedaliero-Universitaria di Careggi</ADDRESS_1>
<ADDRESS_2>Viale della Maternitá</ADDRESS_2>
<CITY>Firenze</CITY>
<ZIP>50134</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19558" MODIFIED="2008-11-10 00:59:03 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rocco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Orlando</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>rocco.orlando@unipd.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical and Surgical Sciences</DEPARTMENT>
<ORGANISATION>University of Padua Medical School</ORGANISATION>
<ADDRESS_1>via Giustiani, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Padova</CITY>
<ZIP>35128</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 049 821 3293</PHONE_1>
<PHONE_2/>
<FAX_1>+39 049 8212151</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-10 01:04:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 13/11/06&lt;/p&gt;&lt;p&gt;New studies sought but none found: 26/05/06&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 26/05/06&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 00:59:21 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="11" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="5" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="9" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-10 00:59:31 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-10 01:01:47 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis</TITLE>
<SUMMARY_BODY>
<P>Probiotics have been proposed as a treatment option for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis because of their balancing role on the flora of the gut that may act as a potential source of hepatotoxic oxidative injury. This review did not identify any randomised clinical trials with probiotics in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Even if the results from pilot studies seem promising, randomised clinical trials are necessary to asses the clinical implication of probiotics therapy in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Non-alcoholic fatty liver disease comprises a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis. Probiotics have been proposed as a treatment option because of their modulating effect on the gut flora that could influence the gut-liver axis. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the beneficial and harmful effects of probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(July 2006), the<I> Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I> (Issue 2, 2006), <I>MEDLINE</I> (1966 to May 2006), and <I>EMBASE </I>(1980 to May 2006). No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials evaluating probiotic treatment in any dose, duration, and route of administration versus no intervention, placebo, or other interventions in patients with non-alcoholic fatty liver disease. The diagnosis was made by history of minimal or no alcohol intake, imaging techniques showing hepatic steatosis and/or histological evidence of hepatic damage, and by exclusion of other causes of hepatic steatosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We had planned to extract data in duplicate and analyse results by intention-to-treat.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No randomised clinical trials were identified. Preliminary data from two pilot non-randomised studies suggest that probiotics may be well tolerated, may improve conventional liver function tests, and may decrease markers of lipid peroxidation.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The lack of randomised clinical trials makes it impossible to support or refute probiotics for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-10 01:01:47 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Non-alcoholic fatty liver disease (NAFLD) is a disorder with histologic features of alcohol-induced fatty liver disease in individuals who consume little or no alcohol. It affects 3% to 25% of the general population (<LINK REF="REF-Lonardo-1999" TYPE="REFERENCE">Lonardo 1999</LINK>; <LINK REF="REF-Angulo-2002" TYPE="REFERENCE">Angulo 2002</LINK>; <LINK REF="REF-Clark-2006" TYPE="REFERENCE">Clark 2006</LINK>). Histologically NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (<LINK REF="REF-Angulo-2002" TYPE="REFERENCE">Angulo 2002</LINK>; <LINK REF="REF-Neuschwander_x002d_T-2003" TYPE="REFERENCE">Neuschwander-T 2003</LINK>; <LINK REF="REF-Liou-2006" TYPE="REFERENCE">Liou 2006</LINK>). NAFLD is usually associated with a number of diseases such as obesity, type 2 diabetes mellitus, hyperlipidaemia, coeliac disease, exposure to various drugs and toxins, and surgical procedures (jejuno-ileal bypass and other operations on the gastrointestinal tract) (<LINK REF="REF-Burt-1998" TYPE="REFERENCE">Burt 1998</LINK>; <LINK REF="REF-Angulo-2002" TYPE="REFERENCE">Angulo 2002</LINK>; <LINK REF="REF-Chitturi-2002" TYPE="REFERENCE">Chitturi 2002</LINK>; <LINK REF="REF-Younossi-2002" TYPE="REFERENCE">Younossi 2002</LINK>). The prevalence of coeliac disease, which may increase intestinal permeability, is about 3% in patients with NAFLD (<LINK REF="REF-Grieco-2001" TYPE="REFERENCE">Grieco 2001</LINK>; <LINK REF="REF-Bardella-2004" TYPE="REFERENCE">Bardella 2004</LINK>). It is still unknown whether <I>Helicobacter pylori</I> infection, which can also be associated with increased mucosal permeability of the gut (<LINK REF="REF-Fukuda-2001" TYPE="REFERENCE">Fukuda 2001</LINK>), may promote the development of NAFLD. </P>
<P>The natural history of NAFLD is uncertain. Patients with fatty liver alone have a benign long-term prognosis (<LINK REF="REF-Day-2006" TYPE="REFERENCE">Day 2006</LINK>), whereas non-alcoholic steatohepatitis (NASH) patients show a much more aggressive course, with development of cirrhosis in up to 26% of patients (<LINK REF="REF-Angulo-1999" TYPE="REFERENCE">Angulo 1999</LINK>; <LINK REF="REF-Ratziu-2000" TYPE="REFERENCE">Ratziu 2000</LINK>; <LINK REF="REF-Dixon-2001" TYPE="REFERENCE">Dixon 2001</LINK>; <LINK REF="REF-Day-2006" TYPE="REFERENCE">Day 2006</LINK>). Indeed, a number of studies suggest that NAFLD may be responsible for cryptogenic cirrhosis (<LINK REF="REF-Brolin-1998" TYPE="REFERENCE">Brolin 1998</LINK>; <LINK REF="REF-Calwell-1999" TYPE="REFERENCE">Calwell 1999</LINK>; <LINK REF="REF-Poonawala-2000" TYPE="REFERENCE">Poonawala 2000</LINK>; <LINK REF="REF-Liou-2006" TYPE="REFERENCE">Liou 2006</LINK>).</P>
<P>The pathophysiology of NAFLD is believed to entail two steps. The first step involves insulin resistance, which induces the development of steatosis. The second step is oxidative stress that activates an inflammatory response and causes NASH (<LINK REF="REF-Chitturi-2001" TYPE="REFERENCE">Chitturi 2001</LINK>; <LINK REF="REF-McCullough-2002" TYPE="REFERENCE">McCullough 2002</LINK>; <LINK REF="REF-McCullogh-2006" TYPE="REFERENCE">McCullogh 2006</LINK>). Additional insults, such as exposure to lipopolysaccharide, certain hepatotoxins, or infectious agents, may also lead to the development of cirrhosis (<LINK REF="REF-Diehl-2000" TYPE="REFERENCE">Diehl 2000</LINK>; <LINK REF="REF-Medina-2004" TYPE="REFERENCE">Medina 2004</LINK>). </P>
<P>An interesting animal model for the study of the disease is represented by leptin-deficient, insulin-resistant <I>ob/ob</I> mice that develop NAFLD spontaneously (<LINK REF="REF-Koteish-2001" TYPE="REFERENCE">Koteish 2001</LINK>). These animals have an increased endogenous production of ethanol due to intestinal bacterial overgrowth (<LINK REF="REF-Cope-2000" TYPE="REFERENCE">Cope 2000</LINK>). Ethanol not only is hepatotoxic, but also increases intestinal permeability, thus enhancing hepatic exposure to other gut bacterial products, such as lipopolysaccharide. Both ethanol- and lipopolysaccharide-related liver damage require the induction of tumour necrosis factor-alfa (TNF-alfa), a proinflammatory cytokine that also produces apoptosis. Indeed, elevated levels of TNF-alfa and a higher prevalence of intestinal bacterial overgrowth have been reported in NASH patients compared to controls (<LINK REF="REF-Wigg-2001" TYPE="REFERENCE">Wigg 2001</LINK>; <LINK REF="REF-Riordan-2002" TYPE="REFERENCE">Riordan 2002</LINK>). Intestinal bacterial overgrowth has also been reported in patients with jejuno-ileal bypass, with small bowel diverticulosis, on long-term total parenteral nutrition, and in those with diabetes mellitus (<LINK REF="REF-Nazim-1989" TYPE="REFERENCE">Nazim 1989</LINK>; <LINK REF="REF-Wigg-2001" TYPE="REFERENCE">Wigg 2001</LINK>), all of whom may develop hepatic steatosis or NASH. Possible factors involved are: lessening of intestinal motility (<LINK REF="REF-Crowell-1994" TYPE="REFERENCE">Crowell 1994</LINK>); excessive consumption of dietary carbohydrate (<LINK REF="REF-Hunnisett-1990" TYPE="REFERENCE">Hunnisett 1990</LINK>); abnormalities in the development of gut-associated lymphoid tissue at an early age (<LINK REF="REF-Hooper-2001" TYPE="REFERENCE">Hooper 2001</LINK>); and TNF-alfa gene polymorphism (<LINK REF="REF-Valenti-2002" TYPE="REFERENCE">Valenti 2002</LINK>). Further evidence of the link between intestinal bacterial overgrowth and hepatic damage is based on the following observations:<BR/>(1) Oral administration of neomycin in ob/ob mice significantly reduces breath ethanol levels (<LINK REF="REF-Cope-2000" TYPE="REFERENCE">Cope 2000</LINK>);<BR/>(2) Antibiotics (metronidazole and tetracycline) reduce hepatic injury in rats with surgically induced intestinal bacterial overgrowth (<LINK REF="REF-Lichtman-1991" TYPE="REFERENCE">Lichtman 1991</LINK>);<BR/>(3) Metronidazole prevents and reverses hepatic steatosis after intestinal bypass for morbid obesity in man (<LINK REF="REF-Drenick-1982" TYPE="REFERENCE">Drenick 1982</LINK>).</P>
<P>These findings imply a critical role for small bowel flora, suggesting that intestinal bacterial overgrowth treatment might reduce ethanol and lipopolysaccharide levels. Probiotics, which are live microbial food supplements or components of bacteria (<LINK REF="REF-Salminen-1998" TYPE="REFERENCE">Salminen 1998</LINK>), may have beneficial effects on human health and have no known negative long-term effects. Moreover, they cause anti-inflammatory responses and protect gut epithelial cells from invasion and adhesion of different pathogens (<LINK REF="REF-Solga-2003" TYPE="REFERENCE">Solga 2003</LINK>; <LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>), including <I>Helicobacter pylori</I> (<LINK REF="REF-Hamilton_x002d_Miller-2003" TYPE="REFERENCE">Hamilton-Miller 2003</LINK>). Their effect on gut permeability remains controversial (<LINK REF="REF-Kennedy-2000" TYPE="REFERENCE">Kennedy 2000</LINK>; <LINK REF="REF-Gotteland-2001" TYPE="REFERENCE">Gotteland 2001</LINK>; <LINK REF="REF-Mangell-2002" TYPE="REFERENCE">Mangell 2002</LINK>; <LINK REF="REF-Resta_x002d_Lenert-2003" TYPE="REFERENCE">Resta-Lenert 2003</LINK>). Probiotics are widely used to treat infectious diarrhoea (<LINK REF="REF-Guandalini-2000" TYPE="REFERENCE">Guandalini 2000</LINK>; <LINK REF="REF-Gionchetti-2002" TYPE="REFERENCE">Gionchetti 2002</LINK>) and have been reported to be effective in preventing relapse in ulcerative colitis (<LINK REF="REF-Venturi-1999" TYPE="REFERENCE">Venturi 1999</LINK>). Moreover, several studies demonstrate that probiotics reduce the risk of pouchitis (<LINK REF="REF-Gionchetti-2000" TYPE="REFERENCE">Gionchetti 2000</LINK>). Probiotics might decrease inflammation and therefore improve NAFLD by the following mechanisms (<LINK REF="REF-Solga-2003" TYPE="REFERENCE">Solga 2003</LINK>):<BR/>(1) Competitive inhibition and possible exclusion of pathogenic strains of intestinal bacterial overgrowth, especially strains that have lower total in vitro binding capacity (<LINK REF="REF-Lee-2000" TYPE="REFERENCE">Lee 2000</LINK>).<BR/>(2) Alteration of the inflammatory effects of pathogenic intestinal bacterial overgrowth through changes in cytokines signalling (<LINK REF="REF-Madsen-2001" TYPE="REFERENCE">Madsen 2001</LINK>).<BR/>(3) Improved epithelial barrier function by modulating cytoskeletal and tight junctional protein phosphorylation (<LINK REF="REF-Resta_x002d_Lenert-2003" TYPE="REFERENCE">Resta-Lenert 2003</LINK>; <LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>).<BR/>(4) Direct decrease in proinflammatory cytokines, eg, TNF-alfa (<LINK REF="REF-Li-2003" TYPE="REFERENCE">Li 2003</LINK>).<BR/>(5) Stimulation of IgA production (<LINK REF="REF-Gronlund-2000" TYPE="REFERENCE">Gronlund 2000</LINK>).</P>
<P>We have been unable to identify any meta-analysis or systematic reviews on probiotics for patients with patients with NAFLD and/or NASH.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the beneficial and harmful effects of probiotics for NAFLD and/or NASH.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-10 01:01:47 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised clinical trials, regardless of publication status, number of patients randomised, language, or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants of any age, sex, or ethnic origin with NAFLD, including NASH and cryptogenic cirrhosis, diagnosed on the basis of the following criteria:<BR/>(1) Imaging techniques showing evidence of hepatic steatosis or steatofibrosis and/or liver biopsy showing histological alterations including simple steatosis, fatty infiltration plus nonspecific inflammation, steatohepatitis, fibrosis, and cirrhosis.<BR/>(2) Daily alcohol intake less than 20 g in women and 40 g in men (<LINK REF="REF-Becker-1996" TYPE="REFERENCE">Becker 1996</LINK>; <LINK REF="REF-Neuschwander_x002d_T-2003" TYPE="REFERENCE">Neuschwander-T 2003</LINK>).<BR/>(3) Exclusion of other causes of hepatic steatosis or steatofibrosis including hepatitis B, hepatitis C, autoimmune hepatitis, and genetic liver disease such as Wilson's disease and haemochromatosis. Participants presenting one or more causes commonly associated with secondary NAFLD (drugs and miscellaneous disorders such as a- or hypo-beta lipoproteinemia, partial lipodystrophy, environmental toxins, or total parenteral nutrition) were also to be excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Probiotics (<I>Lactobacillus</I>, <I>Bifidobacterium</I>, and other live microbial food supplements or components) at any dose, duration, and route of administration, given separately or in combination versus no intervention, placebo, or other interventions. Co-interventions were also to be considered when used equally in both intervention arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome measures</B>
<BR/>(1) All-cause mortality: number of deaths irrespective of cause.<BR/>(2) Hepatic-related mortality.<BR/>(3) Radiological response (degree of fatty liver infiltration assessed by ultrasound, computer tomography scanning, nuclear magnetic resonance, or other imaging techniques) and/or histological response (number of patients with histological improvement/deterioration and changes in the degree of fatty liver infiltration, inflammation, and fibrosis) based on Brunt system or its modifications (<LINK REF="REF-Brunt-2001" TYPE="REFERENCE">Brunt 2001</LINK>; <LINK REF="REF-Harrison-2003" TYPE="REFERENCE">Harrison 2003</LINK>).</P>
<P>
<B>Secondary outcome measures<BR/>
</B>(4) Biochemical response (serum activities of aspartate aminotransferase, alanine aminotransferases, alkaline phosphatases, gamma-glutamyl-transpeptidase, serum total bilirubin, ferritin, and fasting lipid profiles).<BR/>(5) Breath tests (breath ethanol, carbon dioxide levels, D-xylose-lactulose, or other markers of intestinal bacterial overgrowth) (<LINK REF="REF-Nazim-1989" TYPE="REFERENCE">Nazim 1989</LINK>; <LINK REF="REF-Wigg-2001" TYPE="REFERENCE">Wigg 2001</LINK>).<BR/>(6) Adverse events (any adverse events as reported in trials). Depending on availability of data, we planned to classify adverse events as serious or non-serious. Serious adverse events were to be defined as any untoward medical occurrence that was life threatening, resulted in death or persistent or significant disability, or any medical event which might have jeopardised the patient or required intervention to prevent it. All other adverse events were to be considered non-serious.<BR/>(7) Quality-of-life measures.<B>
<BR/>
</B>(8) Cost-effectiveness.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-10 01:01:47 +0100" MODIFIED_BY="[Empty name]">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(July 2006), the<I> Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I> (Issue 2, 2006), <I>MEDLINE</I> (1966 to May 2006), <I>EMBASE</I> (1966 to May 2006). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategies that we applied to the individual databases.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-10 01:00:17 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to follow the instructions given in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>) and the <I>Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2006" TYPE="REFERENCE">Gluud 2006</LINK>).</P>
<P>
<B>Trial selection</B>
<BR/>Two authors (SO and EM) independently assessed whether the identified studies fulfilled the inclusion criteria. Excluded trials were listed in 'Characteristics of excluded studies', with reasons for exclusion being reported accordingly. Since no randomised clinical trials were identified, data extraction, evaluation of methodological quality, and statistical analyses could not be performed.</P>
<P>The following part of the protocol could not be followed because randomised clinical trials that would fulfil the inclusion criteria described in the present protocol could not be found. This is the reason why we have kept the text in future tense and we will change the tense accordingly when trials fulfilling the inclusion criteria are identified in the future.</P>
<P>
<B>Methodological quality of included studies</B>
<BR/>We will define the methodological quality as the confidence that the design and report will restrict bias in the intervention comparison (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>). Due to the risk of overestimation of intervention effects in randomised trials with inadequate methodological quality (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>), we will assess the influence of methodological quality on the treatment effects of probiotics.</P>
<P>
<B>
<I>Generation of the allocation sequence</I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice will be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients. These studies are known as quasi-randomised and will be excluded from the present review when assessing beneficial effects.</LI>
</UL>
<P>
<B>
<I>Allocation concealment </I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<B>
<I>Blinding (or masking)</I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI>Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<B>
<I>Follow-up </I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>Furthermore, we will register whether or not the randomised clinical trials have used an intention-to-treat analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>) and sample-size calculation.</P>
<P>In case data have not been reported sufficiently or are not published at all, we will seek further information by correspondence with the authors.</P>
<P>
<B>Analyses and presentation </B>
<BR/>We will perform the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>).</P>
<P>We will use the software package RevMan 4.2 provided by The Cochrane Collaboration (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>). For dichotomous variables, we will calculate the relative risks with 95% confidence interval. We will use a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). In case of discrepancy between the two models we will report both results, otherwise we will report only the results from the fixed-effect model.</P>
<P>We will perform subgroup analyses depending on the methodological quality of the trials in order to compare the intervention effect in trials with adequate methodological quality to that of trials with unclear or inadequate methodological quality. Heterogeneity will be explored by chi-squared test with significance set at P value 0.10 and the quantity of heterogeneity will be measured by I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>).</P>
<P>Regarding the primary outcome measure, we will include patients with incomplete or missing data in the sensitivity analyses by imputing them (<LINK REF="REF-Hollis-1999" TYPE="REFERENCE">Hollis 1999</LINK>). This kind of approach, as part of sensitivity analyses, will allow to evaluate the robustness of the findings of a meta-analysis as follows:</P>
<UL>
<LI>Available case analysis: data on only those whose results are known, using as denominator the total number of patients who completed the trial;</LI>
<LI>Assuming poor outcome: dropouts from both the probiotics group and control group had the primary outcomes;</LI>
<LI>Assuming good outcome: none of the dropouts from the probiotics group and control group had the primary outcomes;</LI>
<LI>Extreme case favouring probiotics: none of the dropouts from the probiotics group but all of the dropouts from the control group had the first two primary outcomes, and all of the probiotic patients but none of the controls responded.</LI>
<LI>Extreme case favouring control: all dropouts from the probiotics group but none from the control group had the first two primary outcomes, and all of the controls but none of the probiotic patients responded.</LI>
</UL>
<P>For the secondary outcomes, we will adopt 'available case analysis'.</P>
<P>
<B>Bias exploration </B>
<BR/>Funnel plot will be used to provide a visual assessment of whether treatment estimates are associated with study size. The performance of the available methods of detecting biases (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>; <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>) vary with the magnitude of the treatment effect, the distribution of study size, and whether a one- or two-tailed test is used (<LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>). Therefore, we will use the most appropriate method, which has good trade-off in the sensitivity and specificity based on characteristics of the trials to be included in our review.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>The electronic searches of <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I> and the<I> Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library </I>did not produce any references. By searching <I>MEDLINE</I> and <I>EMBASE</I> we retrieved 91 and 297 references, respectively. Of these, we excluded 386 duplicated or clearly irrelevant references (NASH is also a surname, a reagent, and a general hospital). Thus only two references of possible interest were identified and retrieved for evaluation. Both of these studies (<LINK REF="STD-Loguercio-2002" TYPE="STUDY">Loguercio 2002</LINK>; <LINK REF="STD-Loguercio-2005" TYPE="STUDY">Loguercio 2005</LINK>), however, were excluded because they did not fulfil our inclusion criteria. </P>
<P>In addition, we wrote to lead authors working on probiotics in experimental animals, asking them whether they were carrying out studies on the present topic in humans. They replied that no studies of this kind were in progress.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No randomised clinical trials were found.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>We could not find any randomised clinical trials that fulfilled the inclusion criteria of our protocol (<LINK REF="REF-Lirussi-2005" TYPE="REFERENCE">Lirussi 2005</LINK>). <B> </B>
</P>
<P>We identified two non-randomised clinical studies on probiotics in chronic liver diseases of different aetiology, including NAFLD (see description under Excluded studies). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In our search we did not find any randomised clinical trials evaluating probiotics as a therapy for NAFLD or NASH. We only identified small non-randomised studies suggesting that probiotics were not associated with frequent severe adverse effects. Due to the design of these studies we have no knowledge on any potential beneficial or harmful effects. </P>
<P>Animal studies support a pathogenetic role of intestinal bacterial overgrowth for hepatic steatosis, and some beneficial effects of probiotics on liver function tests in this pathological condition (<LINK REF="REF-Lichtman-1991" TYPE="REFERENCE">Lichtman 1991</LINK>; <LINK REF="REF-Pappo-1991" TYPE="REFERENCE">Pappo 1991</LINK>; <LINK REF="REF-Li-2003" TYPE="REFERENCE">Li 2003</LINK>). These studies suggest the presence of an interaction between the intestinal lumen and the liver. In fact, the intestinal flora can increase the release of pro-inflammatory and pro-fibrotic cytokines, thus contributing to the development of liver damage. Probiotics could, therefore, act by inhibiting the growth of pathological strains, improving epithelial barrier function and changing cytokine signalling (<LINK REF="REF-Solga-2003" TYPE="REFERENCE">Solga 2003</LINK>). Intestinal microflora can also influence liver function via endotoxins production (ethanol, ammonium and acetaldehyde). Release of endotoxins modulate Kupffer cells activity and hepatic cytokine production. Thus, probiotics could be considered a potential tool for the prevention and treatment of NASH. </P>
<P>NASH is frequently seen in patients with jejuno-ileal bypass performed for severe obesity and patients in jejunal diverticulosis. Both conditions favour bacterial bacterial overgrowth of the small intestine. Intestinal bacterial overgrowth is more frequent in NASH patients than in controls (<LINK REF="REF-Wigg-2001" TYPE="REFERENCE">Wigg 2001</LINK>). Moreover, there is evidence that oro-cecal transit time is increased in patients with NAFLD, thus supporting the link between endotoxin-induced liver damage and intestinal bacterial overgrowth (<LINK REF="REF-Soza-2005" TYPE="REFERENCE">Soza 2005</LINK>). Antibiotics active on the intestinal microflora are claimed to improve hepatic steatosis in humans receiving total parenteral nutrition (<LINK REF="REF-Pappo-1992" TYPE="REFERENCE">Pappo 1992</LINK>). However, in a recent study, norfloxacin administration had no effect on alanine aminotransferase levels, lactulose breath test, and anti-endotoxin core antibodies titers in nondiabetic patients with NAFLD (<LINK REF="REF-Soza-2005" TYPE="REFERENCE">Soza 2005</LINK>).</P>
<P>The results obtained in the two pilot studies of this review seem promising. They suggest a possible therapeutic role of probiotics in the treatment of a number of chronic liver diseases, including NAFLD. However, despite the rationale for the use of probiotics based on studies in both animals and man, no controlled trials have been performed so far in patients with NAFLD/NASH. We, therefore, need randomised clinical trials of adequate size and methodology assessing the potential beneficial and harmful effect of probiotics. Other points that need to be clarified before probiotics can be considered for clinical practice relate to the type of preparation to be administered (single or multiple strains), the concentration of bacteria, the duration of therapy, and the maintenance of the favourable effect, if any. Some more technical aspects, such as viability of microorganisms during preparation and storage, should also be clarified.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The lack of randomised clinical trials makes it impossible to asses the effect of probiotics administration in patients with NAFLD/NASH. There are no data to support or refute the use of probiotics in clinical practice. We, therefore, suggest that probiotics should not be used for this condition outside randomised clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Randomised clinical trials on probiotics are needed to examine their role as therapy in NAFLD/NASH. The trials need to be of adequate size and adequate methodology and have to be registered in a public register associated with the World Health Organization's platform for registration of clinical trials before inclusion of the first participant, and reported according to the CONSORT guidelines (http://www.consort-statement.org).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Dimitrinka Nikolova and Christian Gluud of The Cochrane Hepato-Biliary Group for their help in the development of the protocol. We thank Gerardo Nardone and Steven F. Solga for helpful comments during peer reviewing of the protocol.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>F Lirussi and S Orando formulated the idea for the review, and revised the protocol and the review. E Mastropasqua and S Orando developed and tested the search strategies for the review, selected trials for the review, and retrieved the data. All authors contributed to the writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Loguercio-2002" NAME="Loguercio 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al</AU>
<TI>Gut-liver axis: a new point of attack to treat chronic liver damage?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loguercio-2005" NAME="Loguercio 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al</AU>
<TI>Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>6</NO>
<PG>540-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Angulo-1999" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Angulo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Angulo P, Keach JC, Batts KP, Lindor KD</AU>
<TI>Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angulo-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Angulo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Angulo P</AU>
<TI>Nonalcoholic fatty liver disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1221-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bardella-2004" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bardella 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bardella MT, Valenti L, Pagliari C, Peracchi M, Fare M, Fracanzani AL, et al</AU>
<TI>Searching for coeliac disease in patients with non-alcoholic fatty liver disease</TI>
<SO>Digestive and Liver Diseases</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>5</NO>
<PG>333-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-1996" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Becker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Becker U, Deis A, Sorensen TI, Gronbæk M, Borch-Johnsen K, Florvall Muller C, et al</AU>
<TI>Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1025-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brolin-1998" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Brolin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Brolin RE, Bradley LJ, Taliwal RV</AU>
<TI>Unsuspected cirrhosis discovered during obesity operations</TI>
<SO>Archives of Surgery</SO>
<YR>1998</YR>
<VL>133</VL>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunt-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Brunt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brunt EM</AU>
<TI>Nonalcoholic steatohepatitis: definition and pathology</TI>
<SO>Seminars in Liver Diseases</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>3-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burt-1998" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Burt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Burt AD, Mutton A, Day CP</AU>
<TI>Diagnosis and interpretation of steatosis and steatohepatitis</TI>
<SO>Seminars in Diagnostic Pathology</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>4</NO>
<PG>246-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calwell-1999" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Calwell 1999" TYPE="JOURNAL_ARTICLE">
<AU>Calwell SH, Oelsner DH, Iezzoni J, Hespenheide EE, Battle EH, Driscoll CJ</AU>
<TI>Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>664-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chitturi-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chitturi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chitturi S, Farrell GC</AU>
<TI>Etiopathogenesis of non-alcoholic steatohepatitis</TI>
<SO>Seminars in Liver Diseases</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>27-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chitturi-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chitturi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al</AU>
<TI>NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>373-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clark JM</AU>
<TI>The epidemiology of nonalcoholic fatty liver disease in adults</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40 Suppl 1</VL>
<PG>S5-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cope-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Cope 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cope K</AU>
<TI>Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>119</VL>
<NO>5</NO>
<PG>1399-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowell-1994" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Crowell 1994" TYPE="JOURNAL_ARTICLE">
<AU>Crowell M D, Cheskin L J, Musial F</AU>
<TI>Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1994</YR>
<VL>89</VL>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Day 2006" TYPE="JOURNAL_ARTICLE">
<AU>Day CP</AU>
<TI>Non-alcoholic fatty liver disease: current concepts and management strategies</TI>
<SO>Clinical Medicine</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>1</NO>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="DeMets 1987" NOTES="&lt;p&gt;JOURNAL-ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87291426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87104256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diehl-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Diehl 2000" TYPE="JOURNAL_ARTICLE">
<AU>Diehl AM</AU>
<TI>Cytokine regulation of liver injury and repair</TI>
<SO>Immunology</SO>
<YR>2000</YR>
<VL>174</VL>
<PG>160-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dixon-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Dixon 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dixon JB, Bhathal PS, O'Brien PE</AU>
<TI>Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>121</VL>
<NO>1</NO>
<PG>91-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drenick-1982" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Drenick 1982" TYPE="JOURNAL_ARTICLE">
<AU>Drenick EJ</AU>
<TI>Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein calorie malnutrition</TI>
<SO>Gastroenterology</SO>
<YR>1982</YR>
<VL>82</VL>
<PG>535-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fukuda-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Fukuda 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, et al</AU>
<TI>Helicobacter pylori infection increases mucosal permeability of the stomach and intestine</TI>
<SO>Digestion</SO>
<YR>2001</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghosh-2004" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ghosh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ghosh S, Van Heel D, Playford RJ</AU>
<TI>Probiotics in inflammatory bowel disease: is it all gut flora modulation?</TI>
<SO>Gut</SO>
<YR>2004</YR>
<VL>53</VL>
<PG>620-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gionchetti-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gionchetti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al</AU>
<TI>Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial</TI>
<SO>Gatroenterology</SO>
<YR>2000</YR>
<VL>119</VL>
<NO>2</NO>
<PG>305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gionchetti-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gionchetti 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gionchetti P, Amadini C, Rizzello F, Venturi A, Palmonari V, Morselli C, et al</AU>
<TI>Probiotics - role in inflammatory bowel disease</TI>
<SO>Digestive and Liver Diseases</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>Suppl 2</NO>
<PG>58-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2001" NOTES="&lt;p&gt;(ENTERED MANUALLY)&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK_SECTION">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>Steatohepatitis (NASH and ASH), Falk Symposium 121</SO>
<YR>2001</YR>
<PG>322-42</PG>
<ED>Leuschner U, James OFW, Dancygier H</ED>
<PB>Kluwer Academic Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2006" NOTES="&lt;p&gt;Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, Klingenberg SL, Koretz R, Liu JP, Myers R, Nikolova D, Pagliaro L, Simonetti R, Sutton R. Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al</AU>
<TI>Hepato-Biliary Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gotteland-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gotteland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gotteland M, Cruchet S, Verbeke S</AU>
<TI>Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>1</NO>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grieco-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Grieco 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grieco A, Miele L, Pignataro G, Pompili M, Rapaccini GL, Gasbarrini G</AU>
<TI>Is coeliac disease a confounding factor in the diagnosis of NASH?</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>596</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gronlund-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gronlund 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gronlund MM, Arvilommi H, Kero P, Lehtonen OP, Isolauri E</AU>
<TI>Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0-6 months</TI>
<SO>Archives of Disease in Childhood, Fetal and Neonatal Edition</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>3</NO>
<PG>F186-F192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guandalini-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Guandalini 2000" TYPE="JOURNAL_ARTICLE">
<AU>Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, et al</AU>
<TI>Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>54-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton_x002d_Miller-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hamilton-Miller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton-Miller JM</AU>
<TI>The role of probiotics in the treatment and prevention of Helicobacter pylori infection</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>4</NO>
<PG>360-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Harrison 2003" TYPE="JOURNAL_ARTICLE">
<AU>Harrison SA, Torgerson S, Hayashi PH</AU>
<TI>The natural history of nonalcoholic fatty liver disease: a clinical histopathological study</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>9</NO>
<PG>2042-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifyng heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2006" NOTES="&lt;p&gt;Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>The Cochrane Library, Issue 4, 2006</SO>
<PB>John Wiley &amp; sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollis-1999" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hollis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hollis S, Campbell F</AU>
<TI>What is meant by intention to treat analysis? Survey of published randomised trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>319</NO>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hooper-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hooper 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI</AU>
<TI>Molecular analysis of commensal host-microbial relationships in the intestine</TI>
<SO>Science</SO>
<YR>2001</YR>
<VL>291</VL>
<PG>881-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunnisett-1990" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hunnisett 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hunnisett A, Howard J, Davies S</AU>
<TI>Gut fermentation (or auto-brewery) syndrome. A new clinical test with initial observations and discussion of clinical and biological implications</TI>
<SO>Journal of Nutritional &amp; Environmental Medicine</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kennedy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy RJ, Hopper M, Deodhar K, Kirk SJ, Gardiner KR</AU>
<TI>Probiotic therapy fails to imoprove gut permeability in a hapten model of colitis</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>12</NO>
<PG>1266-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" NOTES="&lt;p&gt;Journal-Article&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21587469"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koteish-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Koteish 2001" TYPE="JOURNAL_ARTICLE">
<AU>Koteish A, Diehl AM</AU>
<TI>Animal models of steatosis</TI>
<SO>Seminars in Liver Diseases</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>89-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lee YK, Lim CY, Teng WL, Ouwehand AC, Tuomola EM, Salminem S</AU>
<TI>Quantitative approach in the study of adhesion of lactic acid bacteria on intestinal cells and their competition with enterobacteria</TI>
<SO>Applied and Environmental Microbiology</SO>
<YR>2000</YR>
<VL>66</VL>
<PG>3692-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2003" TYPE="JOURNAL_ARTICLE">
<AU>Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al</AU>
<TI>Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>2</NO>
<PG>343-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lichtman-1991" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lichtman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lichtman SN, Keku J, Schwab JH, Sartor RB</AU>
<TI>Hepatic injury associated with small intestinal bacterial overgrowth in rats is prevented by metronidazole and tetracycline</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>2</NO>
<PG>513-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liou-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Liou 2006" TYPE="JOURNAL_ARTICLE">
<AU>Liou I, Kowdley KV</AU>
<TI>Natural history of nonalcoholic steatohepatitis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40, Suppl 1</VL>
<PG>S11-S16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lirussi-2005" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lirussi 2005" NOTES="&lt;p&gt;Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. (Protocol) Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005165. DOI: 10.1002/14651858.CD005165&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Lirussi F, Mastropasqua E, Orando S, Orlando R</AU>
<TI>Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis</TI>
<SO>(Protocol) Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005165. DOI: 10.1002/14651858.CD005165</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lonardo-1999" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lonardo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lonardo A</AU>
<TI>Fatty liver and nonalcoholic steatohepatitis. Where we stand and where are we going?</TI>
<SO>Digestive Diseases</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>2</NO>
<PG>80-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macaskill-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Macaskill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Macaskill P, Walter SD, Irwig L</AU>
<TI>A comparison of methods to detect publication bias in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>641-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madsen-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Madsen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al</AU>
<TI>Probiotics bacteria enhance murine and human intestinal epithelial barrier function</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>121</VL>
<NO>3</NO>
<PG>580-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangell-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Mangell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mangell P, Nejdfoes P, Wang M, Ahrne S, Westrom B, Thorlacius H, et al</AU>
<TI>Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>3</NO>
<PG>511-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCullogh-2006" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="McCullogh 2006" TYPE="JOURNAL_ARTICLE">
<AU>McCullogh AJ</AU>
<TI>Pathophysiology of nonalcoholic steatohepatitis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40 Suppl 1</VL>
<PG>S17-S29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCullough-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="McCullough 2002" TYPE="JOURNAL_ARTICLE">
<AU>McCullough AJ</AU>
<TI>Update on nonalcoholic fatty liver disease</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medina-2004" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Medina 2004" TYPE="JOURNAL_ARTICLE">
<AU>Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R</AU>
<TI>Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>2057-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" NOTES="&lt;p&gt;(Downloaded from MEDLINE)&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98417104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nazim-1989" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Nazim 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nazim M, Stamp G, Hodgson HJF</AU>
<TI>Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1989</YR>
<VL>36</VL>
<PG>349-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neuschwander_x002d_T-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Neuschwander-T 2003" TYPE="JOURNAL_ARTICLE">
<AU>Neuschwander-Tetri BA, Caldwell ST</AU>
<TI>Nonalcoholic steatohepatitis: summary of an AASLD single topic conference</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>5</NO>
<PG>1202-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pappo-1991" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Pappo 1991" TYPE="JOURNAL_ARTICLE">
<AU>Pappo I, Becovier H, Berry EM, Freund HR</AU>
<TI>Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat</TI>
<SO>Journal of Surgical Research</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>2</NO>
<PG>106-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pappo-1992" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Pappo 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pappo I, Bercovier H, Berry EM, Haviv Y, Gallily R, Freund HR</AU>
<TI>Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>6</NO>
<PG>529-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poonawala-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Poonawala 2000" TYPE="JOURNAL_ARTICLE">
<AU>Poonawala A, Nair S, Thuluvath PJ</AU>
<TI>Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>689-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ratziu-2000" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ratziu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al</AU>
<TI>Liver fibrosis in overweight patients</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>6</NO>
<PG>1117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resta_x002d_Lenert-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Resta-Lenert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Resta-Lenert S, Barrett KE</AU>
<TI>Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>988-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2003" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riordan-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Riordan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Riordan SM, Duncombe VM, Thomas MC, Nagree A, Bolin TD, McIver CJ, et al</AU>
<TI>Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>1</NO>
<PG>136-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salminen-1998" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Salminen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al</AU>
<TI>Functional food science and gastrointstinal physiology and function</TI>
<SO>British Journal of Nutrition</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>Suppl 1</NO>
<PG>147-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" NOTES="&lt;p&gt;META-ANALYSIS. JOURNAL-ARTICLE. (Downloaded from MEDLINE)&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 01:01:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95123716"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Solga-2003" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Solga 2003" TYPE="JOURNAL_ARTICLE">
<AU>Solga SF, Diehl AM</AU>
<TI>Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>5</NO>
<PG>681-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soza-2005" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Soza 2005" TYPE="JOURNAL_ARTICLE">
<AU>Soza A, Riquelme A, Robinson G, Alvarez M, Perez-Ayuso, Carlos J, et al</AU>
<TI>Increased orocecal transit time in patients with nonalcoholic fatty liver disease</TI>
<SO>Digestive Disease and Science</SO>
<YR>2005</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1136-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valenti-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Valenti 2002" TYPE="JOURNAL_ARTICLE">
<AU>Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Banci A, Taioli E, et al</AU>
<TI>Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>274-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venturi-1999" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Venturi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Venturi A, Gionchetti P, Rizzello F, Johansson R, Brigidi P, Matteuzzi D, et al</AU>
<TI>Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wigg-2001" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Wigg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wigg AJ</AU>
<TI>The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and TNF alpha in the pathogenesis of non-alcoholic steatohepatitis</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>48</VL>
<PG>206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Younossi-2002" MODIFIED="2008-11-10 01:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Younossi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Younossi ZM, Diehl AM, Ong JP</AU>
<TI>Nonalcoholic fatty liver disease: an agenda for clinical research</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>4</NO>
<PG>746-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Loguercio-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study; not a randomised trial.<BR/>Loguercio 2002 et al tested a mixture of different bacteria strains called LAB (Lactobacillus acidophilus, Bifidus, Rhamnosus, Plantarum, Salivarius, Bulgaricus, Lactis, Casei, Breve) associated to fructo-oligo-saccharides as prebiotic, vitamins (B6, B2, B12, D3, C, folic acid), as well as trace elements. Three groups of patients were enrolled in the study: 12 patients with biopsy-proven chronic hepatitis C, 10 patients with alcoholic cirrhosis all of whom continued drinking alcohol in excess, and 10 patients with biopsy-proven NASH. The NASH patients (all men) were treated with LAB for two months. After treatment, lipid peroxidation indices - malondialdehyde and 4-hydroxinonenal - decreased by 62% and 45%, respectively. TNF-a levels decreased by 18 %. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loguercio-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study; not a randomised trial.<BR/>Loguercio 2005 et al evaluated probiotic therapy in patients with various hepatic diseases. A total of 78 patients were enrolled in the study. Forty-two had a biopsy-proven diagnosis of NAFLD (22) or HCV-related chronic hepatitis (20), whereas the remaining 36 had either a clinical diagnosis of alcoholic liver cirrhosis (20) or HCV-related cirrhosis (16). NAFLD group was younger than the other groups: 37 years versus 50, 52, 59 in alcoholic cirrhosis, HCV-related chronic hepatitis and cirrhosis, respectively. All patients were treated for three months with the probiotic VSL3#, a mixture containing 450 billions of bacteria different strains. Biochemical tests were performed at baseline, at 90 days, and 120 days after starting probiotics. These included routine liver function tests, cytokines (TNF-alfa, interleukin-6, interleukin-10), markers of lipid peroxidation (malonildialdehyde, 4-hydroxinonenal), and S-nitrosothiols, a marker of nitric oxide metabolism. The mixture was well tolerated in all groups with only 4 dropouts because of drug intolerance (meteorism and diarrhoea). Aminotransferase plasma levels significantly decreased in all groups after VSL3# treatment, the effect being maintained after one month of washout in HCV-related chronic hepatitis, NAFLD, and alcoholic cirrhosis groups. Patients with alcoholic cirrhosis exhibited also a significant and persistent decrease of gammaglutamyltranspeptidase. Plasma levels of TNF-alfa, IL-6, and IL-10 did not change significantly in NAFLD patients compared to baseline. Malonildialdehyde and 4-hydroxinonenal were significantly decreased in NAFLD and in alcoholic cirrhosis both at 90 days and 120 days during treatment. S-nitrosothiols plasma levels, elevated in all groups of patients at baseline, showed a significant decrease during treatment, persisting also during the washout period in all groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>NASH = non-alcoholic steatohepatitis<BR/>NAFLD = non-alcoholic fatty liver disease</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-10 01:01:26 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-10 01:01:30 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-10 01:01:30 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-10 01:00:57 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-10 01:01:30 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Date of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Specialised Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>July 2006.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>probiotic* AND steatohepatitis AND nonalcoholic fatty liver disease</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2, 2006.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>probiotic* AND steatohepatitis AND nonalcoholic fatty liver disease</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1966 to May 2006.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(probiotic* OR "natural supplements" OR Lactobacill* OR "Lactococcus lactis" OR "lactic acid bacteria" OR Bifidobacteri* OR VSL#* OR LAB OR Bacterioides OR Clostridium OR Fusobacterium OR Eubacterium OR Peptococcus OR Peptostreptococcus OR Escherichia OR E.Coli OR Veillonella OR Streptococc* OR Saccharomyces OR "Enterococcus faecium" OR "aerobic bacteria*" OR "anaerobic bacteria*" OR microrganism* OR bacteria OR microflora OR "gut microecology" OR "intestinal bacteria*" OR "intestinal flora" OR "commensal bacteria" OR "small bowel bacterial overgrowth" OR "intestinal bacterial overgrowth" OR SIBO OR SBBO OR IBO OR endotoxaemia OR endotoxin* OR "enteric bacterial product*" OR "ethanol test") AND ("non*alcoholic fatty liver" OR "non alcoholic fatty liver" OR "nonalcoholic fatty liver" OR NAFL* OR NASH OR steatohepatitis) NOT "NASH A" NOT "NASH AA" NOT "NASH AD" NOT "NASH AS" NOT "NASH B" NOT "NASH BR" NOT "NASH BW" NOT "NASH C" NOT "NASH CB" NOT "NASH CH" NOT "NASH CL" NOT "NASH CR" NOT "NASH CW" NOT "NASH D" NOT "NASH DC" NOT "NASH DF" NOT "NASH DL" NOT "NASH DR" NOT "NASH DT" NOT "NASH E" NOT "NASH EC" NOT "NASH EJ" NOT "NASH ES" NOT "NASH FD" NOT "NASH FW" NOT "NASH G" NOT "NASH GB" NOT "NASH General Hospital" NOT "NASH GL" NOT "NASH GS" NOT "NASH GV" NOT "NASH H" NOT "NASH HA" NOT "NASH Hall" NOT "NASH HD" NOT "NASH HM" NOT "NASH HW" NOT "NASH J" NOT "NASH JB" NOT "NASH JE" NOT "NASH JF" NOT "NASH JH" NOT "NASH JJ" NOT "NASH JM" NOT "NASH JQ" NOT "NASH JR" NOT "NASH JW" NOT "NASH K" NOT "NASH KA" NOT "NASH KL" NOT "NASH L" NOT "NASH LD" NOT "NASH LJ" NOT "NASH M" NOT "NASH MA" NOT "NASH MC" NOT "NASH ML" NOT "NASH MM" NOT "NASH MW" NOT "NASH N" NOT "NASH P" NOT "NASH PB" NOT "NASH PJ" NOT "NASH PP" NOT "NASH R" NOT "NASH RA" NOT "NASH reaction" NOT "NASH reagent" NOT "NASH RJ" NOT "NASH RS" NOT "NASH RW" NOT "NASH S" NOT "NASH SA" NOT "NASH SM" NOT "NASH solution" NOT "NASH SV" NOT "NASH T" NOT "NASH TA" NOT "NASH TC" NOT "NASH TD" NOT "NASH TE" NOT "NASH TG" NOT "NASH TL" NOT "NASH TW" NOT "NASH University" NOT "NASH W" NOT "NASH WA" NOT "NASH WG"</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to May 2006.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 probiotic*<BR/>2 "natural"<BR/>3 "supplements"<BR/>4 Lactobacill*<BR/>5 "Lactococcus"<BR/>6 "lactis"<BR/>7 "lactic"<BR/>8 "acid"<BR/>9 "bacteria"<BR/>10 Bifidobacteri*<BR/>11 VSL*<BR/>12 LAB<BR/>13 Bacterioides<BR/>14 Clostridium<BR/>15 Fusobacterium<BR/>16 Eubacterium<BR/>17 Peptococcus<BR/>18 Peptostreptococcus<BR/>19 probiotic* or "natural supplements" or Lactobacill* or "Lactococcus lactis" or "lactic acid bacteria" or Bifidobacteri* or VSL* or LAB or Bacterioides or Clostridium or Fusobacterium or Eubacterium or Peptococcus or Peptostreptococcus<BR/>20 Escherichia<BR/>21 E.Coli<BR/>22 Veillonella<BR/>23 Streptococc*<BR/>24 Saccharomyces<BR/>25 "Enterococcus"<BR/>26 "faecium"<BR/>27 "aerobic"<BR/>28 "bacteria*"<BR/>29 "anaerobic"<BR/>30 "bacteria*"<BR/>31 microrganism*<BR/>32 bacteria<BR/>33 Escherichia or E.Coli or Veillonella or Streptococc* or Saccharomyces or "Enterococcus faecium" or "aerobic bacteria*" or "anaerobic bacteria*" or microrganism* or bacteria<BR/>34 microflora<BR/>35 "gut"<BR/>36 "microecology"<BR/>37 "intestinal"<BR/>38 "bacteria*"<BR/>39 "intestinal"<BR/>40 "flora"<BR/>41 "commensal"<BR/>42 "bacteria"<BR/>43 "small"<BR/>44 "bowel"<BR/>45 "bacterial"<BR/>46 "overgrowth"<BR/>47 "intestinal"<BR/>48 "bacterial"<BR/>49 "overgrowth"<BR/>50 microflora or "gut microecology" or "intestinal bacteria*" or "intestinal flora" or "commensal bacteria" or "small bowel bacterial overgrowth" or "intestinal bacterial overgrowth"<BR/>51 SIBO<BR/>52 SBBO<BR/>53 IBO<BR/>54 endotoxaemia<BR/>55 endotoxin*<BR/>56 "enteric"<BR/>57 "bacterial"<BR/>58 "product*"<BR/>59 "ethanol"<BR/>60 "test"<BR/>61 #50 or SIBO or SBBO or IBO or endotoxaemia or endotoxin* or "enteric bacterial product*" or "ethanol test"<BR/>62 "non*alcoholic"<BR/>63 "fatty"<BR/>64 "liver"<BR/>65 "non"<BR/>66 "alcoholic"<BR/>67 "fatty"<BR/>68 "liver"<BR/>69 "nonalcoholic"<BR/>70 "fatty"<BR/>71 "liver"<BR/>72 NAFL*<BR/>73 NASH<BR/>74 steatohepatitis<BR/>75 "non*alcoholic fatty liver" or "non alcoholic fatty liver" or "nonalcoholic fatty liver" or NAFL* or NASH or steatohepatitis<BR/>76 #19 or #33 or #50 or #61<BR/>77 #75 and #76</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>